Brachial Plexitis During Maintenance Atezolizumab After Palliative Radiotherapy for Cervical Spine Metastasis in Lung Cancer.

IF 1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Internal Medicine Pub Date : 2025-02-18 DOI:10.2169/internalmedicine.4623-24

Riko Kamada, Makoto Hibino, Saki Nakachi, Hikari Higa, Shigehiro Watanabe, Kazunari Maeda, Tetsuri Kondo

引用次数: 0

Abstract

We present the case of a patient with lung cancer who developed brachial plexitis following treatment with immunochemotherapy, which included atezolizumab and palliative radiotherapy for a metastatic cervical spine tumor. This case highlights the importance of considering immune-related adverse events (irAEs) when initiating immune checkpoint inhibitor therapy, in addition to other recognized causes such as radiation, tumor compression and invasion, and paraneoplastic syndromes. While brachial plexitis has been reported as an irAE associated with programmed cell death 1 (PD-1) antibodies, this is the first report associated with the administration of programmed cell death ligand 1 (PD-L1) antibodies.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Internal Medicine 医学-医学：内科

CiteScore

1.90

自引率

8.30%

发文量

审稿时长

2.2 months

期刊介绍： Internal Medicine is an open-access online only journal published monthly by the Japanese Society of Internal Medicine. Articles must be prepared in accordance with "The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see Annals of Internal Medicine 108: 258-265, 1988), must be contributed solely to the Internal Medicine, and become the property of the Japanese Society of Internal Medicine. Statements contained therein are the responsibility of the author(s). The Society reserves copyright and renewal on all published material and such material may not be reproduced in any form without the written permission of the Society.